Cue Biopharma, Inc. (NASDAQ:CUE – Get Rating) saw a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 717,000 shares, a decline of 5.6% from the November 30th total of 759,900 shares. Based on an average trading volume of 162,500 shares, the days-to-cover ratio is currently 4.4 days.
Analyst Upgrades and Downgrades
Separately, Piper Sandler began coverage on Cue Biopharma in a research note on Sunday, November 20th. They set an "overweight" rating and a $7.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Cue Biopharma presently has an average rating of "Buy" and an average price target of $15.60.
Get
Cue Biopharma alerts:
Cue Biopharma Stock Down 6.7 %
NASDAQ CUE opened at $2.66 on Wednesday. The company has a current ratio of 6.04, a quick ratio of 6.04 and a debt-to-equity ratio of 0.18. Cue Biopharma has a one year low of $2.18 and a one year high of $12.20. The stock has a 50 day moving average price of $3.12 and a 200-day moving average price of $2.95.
Cue Biopharma (NASDAQ:CUE – Get Rating) last released its quarterly earnings results on Monday, November 14th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.07. Cue Biopharma had a negative return on equity of 77.78% and a negative net
margin of 500.66%. The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.65 million. On average, equities analysts forecast that Cue Biopharma will post -1.43 EPS for the current year.
Institutional Trading of Cue Biopharma
Hedge funds and other institutional investors have recently bought and sold shares of the business. Newbridge Financial Services Group Inc. increased its stake in Cue Biopharma by 200.0% in the second quarter. Newbridge Financial Services Group Inc. now owns 12,000 shares of the company's stock worth $30,000 after purchasing an additional 8,000 shares during the period. Prosight Management LP grew its position in shares of Cue Biopharma by 82.2% during the 1st quarter. Prosight Management LP now owns 1,510,282 shares of the company's stock worth $7,370,000 after buying an additional 681,240 shares in the last quarter. Sanders Morris Harris LLC grew its position in shares of Cue Biopharma by 15.2% during the 3rd quarter. Sanders Morris Harris LLC now owns 848,048 shares of the company's stock worth $2,020,000 after buying an additional 111,836 shares in the last quarter. Good Life Advisors LLC bought a new position in shares of Cue Biopharma during the 2nd quarter worth $142,000. Finally, P.A.W. Capital Corp grew its position in shares of Cue Biopharma by 16.7% during the 2nd quarter. P.A.W. Capital Corp now owns 175,000 shares of the company's stock worth $436,000 after buying an additional 25,000 shares in the last quarter. Hedge funds and other institutional investors own 31.87% of the company's stock.
Cue Biopharma Company Profile
(Get Rating)
Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers.
Read More
- Get a free copy of the StockNews.com research report on Cue Biopharma (CUE)
- Is First Solar Stock is Flying Too Close to the Sun?
- What's the Outlook for META Stock in 2023?
- Can Investors Cash In On PayPal?
- These 3 Tech Stocks Are in for a Happier New Year
- Tyson Foods: Growth and Momentum at a Reasonable Price
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
